Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post-hoc analyses from the Scleroderma Lung Study I and II

Documenti analoghi

• Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II
  di: Volkmann, Elizabeth R., et al.
  Pubblicazione: (2020)
• Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
  di: Kafaja, Suzanne, et al.
  Pubblicazione: (2018)
• Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)
  di: Khanna, Dinesh, et al.
  Pubblicazione: (2019)
• Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial
  di: Tashkin, Donald P, et al.
  Pubblicazione: (2016)
• Mycophenolate versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II
  di: Volkmann, Elizabeth R., et al.
  Pubblicazione: (2017)